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Monitoring of testosterone replacement therapy re-
quires a reliable method for testosterone measure-
ment. Determination of salivary testosterone, which
reflects the hormone’s biologically active plasma frac-
tion, is a superior technique for this purpose. The aim
of the present study was to establish a new sensitive
time-resolved fluorescence immunoassay for the accu-
rate measurement of testosterone levels in saliva and
to validate it by monitoring testosterone replacement
therapy in eight hypogonadal men.
A clinical phase I- study with the new ester testoste-
rone buciclate was performed to search for new tes-
tosterone preparations to produce constant serum
levels in the therapy of male hypogonadism. After two
control examinations eight male patients with primary
hypogonadism were randomly assigned to two treat-
ment groups (n= 2x4) and given single doses of either
200 mg (group I) or 600 mg (group II) testosterone
buciclate intramuscularly. Saliva and blood samples
were obtained 1, 2, 3, 5 and 7 days post injection and
then weekly for three months.
The time-resolved fluorescence immunoassay for
salivary testosterone shows a detection limit of 
16 pmol/l, an intra-assay CV of 8.9 % (at a testosterone
concentration of 302 pmol/l), an inter-assay CV of
8.7 % (at a testosterone concentration of 305 pmol/l)
and a good correlation with an established radioim-
munsassay of r=0.89. The sample volume required by
this method is only 180 µl for extraction and duplicate
determination. The assay procedure requires no more
than three hours.
In group I (200 mg) testosterone did not increase to
normal levels either in saliva or in serum. However, in
group II, androgen levels increased significantly and
were maintained in the normal range for up to 12
weeks with maximal salivary testosterone levels of
303 ±18 pmol/l (mean±SE) and maximal testosterone
levels of 13.1 ±0.9 nmol/l (mean±SE) in serum in study
week 6 and 7.
The time-resolved fluorescence immunoassay for
salivary testosterone provides a useful tool for moni-
toring androgen status in men and women and is well
suited for the follow-up of testosterone replacement
therapy on an outpatient basis. The long-acting ester
testosterone buciclate is a promising agent for substi-
tution therapy of male hypogonadism and in combina-
tion with testosterone monitoring in saliva offers an
interesting new perspective for male contraception.
Key words: Testosterone; Saliva; Testosterone buci-
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Introduction
In monitoring the function of steroid-producing or-
gans, the quantification of steroid hormones in saliva is
a useful, non-invasive approach for the assessment of
biologically active hormone concentrations (1–3). The
appearance in saliva of steroids such as testosterone is
flow rate-independent and is caused by their free diffu-
sion from blood plasma to saliva through the epithelial
cells of the salivary gland (2, 4, 5), which is comparable
with the physiological process of entering target cells.
It is likely, therefore, that the non-sex hormone-binding
globulin(SHBG)-bound fraction is readily available to
target cells physiologically active, and that this fraction
is identical with salivary testosterone (6–8). In plasma,
the non-SHBG-bound fraction mainly represents the
unbound fraction (1–3 %) and the albumin-bound hor-
mone fraction (20–80 %) in plasma (9, 10). Because of
the non-invasive and stress-free technique of sample
collection as well as the ease of multiple sampling by
the patient himself, salivary hormone assays are being
used increasingly in psychological (11, 12), anthropo-
logical (13, 14), and field studies (15). From a clinical
point of view, salivary testosterone results not only
seem to be of greater diagnostic use in hirsutism than
any of the currently used serum androgen parameters
(16), but also seem to be well suited for monitoring tes-
tosterone replacement therapy.
Traditionally, salivary testosterone has been meas-
ured by immunoassays using 3H- or 125l-labelled testos-
terone-derivatives as tracers. In order to exploit the ex-
ceptional affinity of the avidin-biotin system (Ka = 1015
M-1) (17), a low molecular weight testosterone-biotin
conjugate for use as a tracer in a testosterone immu-
noassay was synthesized. With this stable tracer as a
tool, a time-resolved fluorescence immunoassay (TR-
FIA) was established as a new, non-isotopic approach
to the measurement of salivary testosterone.
Commonly used testosterone esters, given either
intramuscularly or orally, correct many symptoms of
testosterone deficiency, but their pharmacokinetics are
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still unfavourable. The potential application of andro-
gens to substitution therapy of aging men (18) and to the
surveillance of male contraception (19, 20), however,
makes the increasing use of androgen preparations
likely. To assess the pharmacokinetics and pharmaco-d-
ynamics of the new WHO and National Institute of
Health (NIH) ester, testosterone buciclate, in hypogona-
dal men, a clinical phase I-study was performed (21, 22).
This study was monitored by the measurement of
salivary testosterone with the newly established TR-
FIA.
Subjects and Methods
Establishment and validation of the TR-FIA for the measure-
ment of salivary testosterone
Synthesis of a testosterone 3-(O-carboxymethyl)-oxime 
(testosterone-3-CMO)-biotin conjugate
Fifty µmol (18.075 mg) of testosterone-3-CMO (Sigma, Dei-
senhofen, Germany, Cat. No. T-8390) were dissolved in 200 µl
of dry, amine free N,N´-dimethylsulfoxide (DMSO) (Merck,
Darmstadt, Germany, Cat. No. 2952). Equimolar amounts
(6.31 mg and 11.18 mg respectively) of N-hydroxysuccinimide
(NHS) (Sigma, Cat. No. H-7377) and N,N´-dicyclohexylcarbo-
diimide (Sigma, Cat. No. D-3128) were dissolved each in 50 µl
of DMSO and added to the testosterone-3-CMO. This reaction
mixture was left at room temperature in the dark for 24 hours
during which time the testosterone-3-CMO was converted
into its NHS ester, and needle-like crystals of dicyclohexyl
urea appeared. For coupling of the testosterone-N-hydroxy-
succinimide ester to biotin (23), 50 µmol (18.66 mg) of biotin-
amidocaproyl hydrazide (Sigma, Cat. No. B-3770), were dis-
solved in 200 µl of DMSO. The biotin derivative was added to
the reaction mixture which was left at room temperature for
another 24 hours in the dark. The proposed mechanism of re-
action and structure of the final product are shown in Figure 1
(24). The course of the reaction was monitored by thin layer
chromatography under UV-light.
Purification of the testosterone-3-CMO-biotin conjugate
Aliquots of this reaction mixture were applied to a 10 x 400 mm
Trisacryl GF 05 M (Serva, Heidelberg, Germany, No. 67010) 
column after 1:10 (v/v) dilution in column buffer (50 mmol/l
Tris-HCl adjusted to pH 7.8 with 1 mol/l HCl) using fast perform-
ance liquid chromatography (FPLC). The elution pattern of the
column showed two well-separated peaks.
Characterization of the testosterone-3-CMO-biotin conjugate
The testosterone content of the fractions was analyzed by a
commercially available radioimmunoassay (RIA-mat Testos-
teron, Byk Sangtec Diagnostica GmbH, Dietzenbach, Ger-
many, No. 322.451). Testosterone concentrations corre-
sponded to the absorbance at 254 nm of the column eluate. In
addition the fractions were tested as tracer for maximal bind-
ing and displacement by a 6.93 nmol/l testosterone standard.
Determinations were performed in duplicate, and the ratio
between the signal obtained at maximal binding and the dis-
placement by the 6.93 nmol/l standard was calculated. The
second of the two peaks at 254 nm showed the highest bind-
ing ratio and apparently contained the testosterone-biotin
conjugate, while the first peak contained mainly uncoupled
testosterone. Finally, the biotin content of the fractions was
measured with an in-house TR-FIA for biotin determination
and confirmed the previous findings by showing significant
amounts of biotin in the second peak of the elution pattern.
Testosterone antiserum
Testosterone antiserum was kindly provided by Prof. F. Bid-
lingmaier (Bonn, Germany). Specificity of the antiserum was
determined by addition of increasing amounts of cross-react-
ing steroids as the unknown sample in the immunoassay de-
scribed here. The doses of testosterone and cross-reacting
steroid hormone effectively displacing 50% of the tracer from
the antibody (ED-50) were compared and the respective con-
centrations were expressed as ED-50 (testosterone): ED-50 
(cross-reacting steroid) x 100 (%).
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Fig. 1 Pathway of synthesis and proposed chemical structure of the testosterone-biotin tracer conjugate.
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Saliva sampling
Saliva samples were taken at two control examinations,
shortly before and 1 hour and 1, 2, 3, 5, 7 days after testoste-
rone buciclate injection, and then weekly up to week 16.
Of three existing types of saliva sampling devices (“Sali-
vette”, Sarstedt, Nümbrecht, Germany) only one type 
(No. 51.1534.002) can be used without a positive bias in the
analytical results (25, 26). This type of “salivette” consists of a
40 x 9 mm non-glued polyester wool swab wrapped in poly-
propylene film, an inner and an outer polystyrene tube. For
sampling, ten minutes after rinsing the mouth with water (but
no tooth brushing, to avoid gingival microlesions) (27), the
polyester wool swab is kept in the mouth or chewed on for 
0.5 – 2 min. The swab is then transferred to the inner of the two
polystyrene tubes and the sample is frozen. Unpreserved sa-
liva samples stored unrefrigerated have been shown to yield
satisfactory results for male subjects, but lead to increased
measured concentrations for female subjects (28). In our own
experiments a storage time up to three months at room tem-
perature did not have significant influence on the salivary tes-
tosterone results. Storage time of frozen samples does not
seem to affect the reliability of the measurement of salivary
steroids (25). By centrifugation of the thawed samples prior to
analysis, the salivary liquid is transferred to the outer tube. Sa-
liva samples which on inspection are contaminated with
blood are excluded from the analysis (29).
Assay design
Affinity purified swine anti-rabbit immunoglobulin (Dako,
Hamburg, Germany, No. Z 400) was immobilized on to micro-
titre plates (Maxisorp, Nunc, Roskilde, Denmark, No. 4-42404)
at 200 ng per well in 200 µl of 50 mmol/l trisodium phosphate
adjusted to pH 9.6 with 1 mol/l HCl. These plates can be stored
at 4 °C in the coating buffer up to three months without appar-
ent loss of binding activity for testosterone and the testoste-
rone-biotin conjugate. After an incubation for at least 12 hours
plates were washed three times in an automatic plate washer
(DELFIA platewash, Pharmacia, Uppsala, Sweden, No. 1296–
024), then 200 µl of the antigen-specific testosterone anti-
serum diluted 1:100000 in assay buffer (50 mmol/l Tris-HCl, 
150 mmol/l NaCl, 5 g/l bovine serum albumin (BSA) (SIGMA,
Cat. No. A-7906), 0.5 g/l bovine g-globulin (SIGMA, Cat. No. 
G-7516), 0.5 g/l NaN3 (Merck, Cat. No. 6688), 0.1 g/l Tween 40 
(Sigma, Cat. No. P 1504), and 7.87 mg/l Diethylenetriamine-
pentaacetic acid (DTPA) (Sigma, Cat. No. D-6518) adjusted to
pH 7.7 with 1 mol/l HCl) were added and stored for 24 hours to
two months at 4 °C. Testosterone standards were prepared by
diluting an ethanolic, photometrically calibrated stock solution
of testosterone (260 mg/l) in “artificial saliva” containing (per
100 g): sorbitol (3.0 g), potassium chloride (0.150 g), sodium
chloride (0.085 g), calcium chloride dihydrate (0.015 g), hy-
droxyethyl cellulose (0.120 g) and water up to 100.0 g. The anti-
body-coated plates were washed and 50 µl of standard or ex-
tracted sample were pipetted to the bottom of the microtitre
plate wells. Subsequently, 50 µl of the testosterone-biotin con-
jugate as the tracer and 100 µl of assay buffer were added. In-
cubation was allowed to proceed for two hours at ambient
temperature on a horizontal microtitre plate  shaker (DELFIA
Plateshake, Pharmacia, No. 1296–001).
Endpoint determination
The incubation was terminated by washing the plates three
times, and 20 ng of streptavidin-europium conjugate (Phar-
macia, No. 1244–360) diluted in 200 µl assay buffer were
added to each well. The reaction was allowed to proceed for
30 minutes on a horizontal shaker. After a 6-fold wash step,
“enhancement solution” (Pharmacia, No. 1244–105) was
added, which transforms the europium coupled to streptavi-
din into a highly fluorescent complex (30). TR-FIA measure-
ment was carried out in a 1232 DELFIA fluorometer (Pharma-
cia, No. 1232–002, Wallac, Turku, Finland).
Reference radioimmunoassay
The established RIA for salivary testostererone, with which
the TR-FIA was compared, requires 1 ml to 3 ml saliva for ex-
traction with ether and salivary testosterone determination
(31).
For the RIA an anti-testosterone-3-CMO-BSA-serum was used
and the only steroid which significantly cross-reacted was 
5a-dihydrotestosterone (60 %). Sensitivity of the saliva RIA,
taken as the value on the standard curve at two standard devi-
ations below the maximum specific binding, was 35 pmol/l.
The intra-and inter-assay coefficients of variation were 3.7 %
and 13.8 %, respectively.
Sample preparation
In order to eliminate matrix interference, saliva samples 
(180 µl) were extracted by addition of 1.8 ml of dichlorome-
thane (Merck, Darmstadt, Germany) containing 50 mg/l poly-
ethyleneglycol 10000 (Merck, Darmstadt, Germany). Samples
were mixed for 15 minutes on a horizontal shaker. The sam-
ples were then left unagitated for 10 minutes to allow phase
separation. Subsequently, 1.65 ml of the organic solvent was
carefully removed and evaporated using a water bath and the
residue was redissolved in the “artificial saliva” (165 µl). Re-
covery of this extraction step was determined by measure-
ment of control samples containing a known amount of 
tritium-labelled testosterone (Bio Merieux, Nümbrecht, Ger-
many) in a b-scintillation counter (Berthold, Bad Wildbad, Ger-
many).
Blood samples
Blood samples for hormone determinations were drawn
between 8.00 and 10.00 h at two control examinations, shortly
before and 1 h and 1, 2, 3, 5, 7 days after testosterone buciclate
injection, and then weekly up to week 16. Blood samples for
hormone determinations were separated at 800 x g and stored
at –20 °C until assayed.
Immunoassay serum
SHBG was determined by highly specific fluoroimmunoas-
say (DELFIA SHBG, Pharmacia GmbH, Freiburg, Germany)
(22, 32). The detection limit for SHBG was 6.3 nmol/l. The
intra- and inter-assay coefficients of variation for SHBG were
5.3 % and 7.2 %. In our laboratory the normal range for adult
males for SHBG is 11–71 nmol/l. Testosterone and dihydro-
testosterone were separated in extracted serum samples by
high performance liquid chromatography before measure-
ment by RIA, as described earlier (33). The detection limits
for testosterone and dihydrotestosterone were 0.28 and 
0.14 nmol/l, respectively. The intra- and inter-assay-coeffi-
cients of variation for testosterone were 6.8 % and 9.8 %, re-
spectively, and for dihydrotestosterone 8.5 % and 13.4 %, 
respectively. The lower normal limit for androgens (sum of
testosterone and dihydrotestosterone) after separation by
high performance liquid chromatography was 10 nmol/l and
the upper normal limit for dihydrotestosterone is 2.9 nmol/l
in our laboratory.
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Patients and medication
The study protocol of the phase I study with testosterone bu-
ciclate was approved by the Steering Committee of the WHO
Task Force on Methods for the Regulation of Male Fertility, by
the WHO Toxicology Group, by the WHO Scientific and Ethical
Review Group and by the WHO Secretariat Committee on Re-
search Involving Human Subjects, as well as by the Ethics
Committee of the University of Münster and the State Medical
Board. Eight adult patients (28–48 years) with primary hypo-
gonadism without additional diseases gave informed consent
and were enrolled in the study. After two control examina-
tions the patients were randomly allocated to either of two
treatment groups. Two-hundred milligrams of testosterone
buciclate (0.8 ml injection vol, one injection site) were admin-
istered by injection to the medial gluteal muscle on day 0 to
study group I (n=4; age, 37.8 ± 8.2 years (mean ± SD); body
weight, 78.2 ± 12.6 kg; height, 181.7 ± 5.8 cm). Similarly, 
600 mg testosterone buciclate (2.4 ml injection vol, one injec-
tion site) were given to study group II (n=4; age, 32.3 ± 3.4
years; body weight, 84.7 ± 7.8 kg; height, 183.6 ± 6.0 cm).
The androgen ester testosterone buciclate was prepared by
Palmer Research (Holywell, Great Britain) under WHO aus-
pices under Good Manufacturing Practice conditions. After
wet milling of crystalline testosterone buciclate obtain at least
75 % of particles in the size range of 10–50 µm, the drug was
sterilized by g-radiation and suspended in sterile aqueous so-
lution. The suspension was shaken vigorously for 1 minute
before injection. The batch used for all injections had a con-
centration of 250 g/l testosterone buciclate, which corre-
sponds to a concentration of 158.6 g/l (0.55 mol/l) unesterified
testosterone. The clinical data and hormone serum levels of
this study have been published elsewhere (21).
Statistical methods
Variation over time and differences between study groups were
evaluated by multifactorial analysis of variance for repeated
measures. Computations were performed using statistical soft-
ware Statview® for Macintosh, version D-4.5, statistical soft-
ware package SPSS/PC+, version 4.0 (SPSS, Inc., Chicago, IL,
USA) and Statgraphics Plus, version 5.2 (STSC, Inc., Rockville,
MD, USA). When necessary, variables were logarithmically
(log) transformed before analysis to achieve normal distribu-
tion. Two sided p-values < 0.05 were considered to indicate 
significance. In general, results are given as the mean ± SE.
Results
Assay characteristics of the new TR-FIA for salivary
testosterone
The new TR-FIA requires as little as 180 µl of saliva for ex-
traction and triplicate determination, and the assay is
easy to handle and takes 6 hours for the determination of
80 samples, including the sample extraction. The testo-
sterone-biotin tracer is stable for at least three years.
Specificity
The displacing potency of potentially cross-reacting ster-
oids was investigated by addition of increasing doses of
steroids as the unknown sample in the immunoassay
procedure, and comparison of ED-50. In this assay, a-di-
hydrotestosterone had a relative displacing potency of
19.5 %, androstenedione 9.7 %, 6-b-hydroxytestosterone
6.2 %, and 11-b-hydroxytestosterone 3.6 %.
Sensitivity
The sensitivity of the TR-FIA was defined as the inter-
cept with the displacement curve of the mean minus
two standard deviations of a determination of the zero
standard (n=30). The sensitivity was 16 pmol/l.
The mean 50% intercept of a typical displacement
curve was 220 pmol/l.
Imprecision
The intra-assay coefficients of variation were deter-
mined by a measurement of three different saliva 
samples (n=36) with testosterone concentrations of
302.0 pmol/l, 158.5 pmol/l and 125.0 pmol/l. The intra-
assay imprecision for the salivary testosterone concen-
trations of 302 pmol/l, 158.5 pmol/l and 125.0 pmol/l
(n=36) was 8.9 %, 14.6 % and 11.4 %, respectively.
Two different samples were determined in 24 con-
secutive assays for calculation of the inter-assay impre-
cision. The inter-assay coefficient of variation for the
concentrations of 182.4 pmol/l and 304.8 pmol/l was 
7.9 % and 8.7 %, respectively (n=24).
Recovery
The mean recovery of the extraction step was 93 % (for
n=12).
Salivary samples with testosterone concentrations
of 236.5 pmol/l, 210.5 pmol/l, 182.0 pmol/l and 131.1
pmol/l were serially diluted with zero-standard. The
measured concentrations were compared with the ex-
pected concentrations and expressed as a percentage
of the expected value. The mean recoveries were 
104.1 %, 94.2 %, 93.6 %, and 95.6 %, respectively.
Correlation of salivary testosterone TR-FIA with RIA
Salivary samples (n=132, concentration range: 
37 pmol/l – 403 pmol/l) from healthy men and women
were analyzed using both the established RIA adapted
for salivary testosterone measurement and the new
TR-FIA. The correlation found was significant (r= 0.89,
p<0.0001) (Fig. 2)
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Fig. 2 Comparison of the new time-resolved fluorescence
immunoassay (TR-FIA) and an established radioimmunoassay
(RIA) (31) for the measurement of testosterone in saliva regres-
sion analysis: y= 1.076 + 0.505 x; r=0.89; p<0.0001 (n=132 sali-
vary samples; concentration range: 37 pmol/l – 403 pmol/l).
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Monitoring of testosterone replacement therapy in hy-
pogonadal men in saliva
After injection of 600 mg testosterone buciclate, sali-
vary testosterone increased from 203 ± 36 pmol/l (mean
± SE) to 303 ± 18 pmol/l (mean ± SE) and was main-
tained in the normal range (230 pmol/l – 570 pmol/l as
validated for the TR-FIA) for up to eleven weeks. How-
ever, after injection of 200 mg testosterone buciclate,
salivary testosterone did not increase significantly. The
time course of increase of salivary testosterone was
parallel to that of serum androgen levels for both
groups. (Fig. 3)
Correlation of salivary testosterone concentration with
serum SHBG, oestradiol, dihydrotestosterone and tes-
tosterone
The salivary testosterone levels measured after injec-
tion of testosterone buciclate showed a negative corre-
lation with SHBG in serum (r= 0.50; p<0.001), a positive
correlation with serum oestradiol (r=0.52; p<0.001), a
positive correlation with serum dihydrotestosterone
(r=0.37; p<0.001) and a weak, but significant, correla-
tion with total serum testosterone (r=0.22; p=0.009).
Discussion
We have established a new method for the measure-
ment of salivary testosterone and used it for the moni-
toring of testosterone replacement therapy with the an-
drogen ester testosterone buciclate in eight hypogona-
dal men.
When multiple sampling is required, as in the moni-
toring of testosterone replacement therapy, salivary
hormone measurement is non-invasive and stress-
free. The methods are accurate and reliable. (34). Fre-
quent collecting and mailing of saliva samples is prac-
ticable for the patients and does not require assistance
of medically trained staff (25).
The newly established TR-FIA is characterized by a
number of advantageous features. A sample volume
of not more than 180 µl of saliva was sufficient for the
accurate measurement of salivary testosterone, while
comparable methods (28, 31) require a sample volume
between 500 µl and 5000 µl. The non-isotopic method
is easy to perform, inexpensive, takes a total of three
hours incubation time and has a lower detection limit
of 16 pmol/l. Sensitivity and accuracy of this assay
should allow the measurement of salivary testoste-
rone in women and even pre-pubertal children. Corre-
lation with an established assay was good (r=0.89). A
slope of the regression line of only b=0.51 is most
probable due to the use of different standards. The
employed biotintestosterone conjugate has a molecu-
lar size weight of 740.5 Da which is comparable with
the analyzed steroid (288.4 Da) and can be stored for
more than 24 months without significant loss of activ-
ity. The use of biotin as a primary probe provides a
signal amplification system (23) and also has the ad-
vantage of a versatile endpoint determination: this
tracer can be detected using EIA readers, TR-fluorom-
eters, luminometers or in conventional g-counting,
thereby reducing between-laboratory variance. The
antibody used is highly specific. The assay procedure
is simple, reliable and rapid.
Testosterone in serum is largely bound to SHBG and
albumin. The unbound testosterone and corticoster-
oid-binding globulin-bound testosterone fractions are
minimal. The unbound testosterone is biologically ac-
tive, while SHBG-bound testosterone is not. The bio-
availability of albumin-bound testosterone is contro-
versial (35–37), but some studies suggest that
bioavailable testosterone includes circulating free tes-
tosterone and a large proportion of albumin-bound tes-
tosterone (6, 38). An argument in favour of this theory
is that the half-dissociation time of testosterone from
SHBG is relatively long (<20 sec), while in contrast, the
half-dissociation time of testosterone from albumin 
(<1 sec) is within the probable capillary transit time.
Therefore these fractions may be available to target tis-
sues and saliva, respectively. Salivary testosterone lev-
els are independent of salivary flow rate (5) and, due to
the rapid passage of steroid hormones from blood to
saliva, despite enzymes such as 5-a-reductase being
present in salivary glands (39), steroid metabolism is
probably not an important source of error in the meas-
urements of testosterone in saliva (40). The importance
of metabolism of testosterone in salivary glands is still
unclear (41, 42), but recent results of in vitro experi-
ments (40) and the excellent correlation of salivary tes-
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Fig. 3 Salivary testosterone concentrations and serum an-
drogen (sum of serum testosterone and serum dihydrotestos-
terone concentrations) levels in hypogonadal men after injec-
tion of testosterone buciclate (a; 600 mg testosterone
buciclate, n=4) (b; 200 mg testosterone buciclate n=4).
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tosterone with total-, free- and particularly non-SHBG-
bound testosterone (16), suggest that metabolism of
steroids in human salivary glands does not affect the
level of salivary testosterone. Thus, salivary testoste-
rone appears to reflect the biological activity of the hor-
mone.
Development of accurate assays for analytes present
at low picomolar concentrations in body fluids is a de-
manding task. The appearance of an unexpected posi-
tive bias in salivary testosterone assays which was de-
pendent on the material chosen for saliva sampling is
an example of the encountered difficulties. In this con-
text we could confirm earlier results of Dabbs (28), who
detected testosterone-like immunoreactivity in cotton
wool swabs used in saliva sampling devices. In search
for an optimal method of saliva sampling for the testos-
terone TR-FIA, the eluates from three of the existing
types of “salivettes” were measured. These were
soaked with 1 ml of saline under sterile conditions, fro-
zen, thawed and centrifuged as described above for the
pretreatment of salivary testosterone samples. In two
of the extracted eluates we found testosterone concen-
trations in a range corresponding to normal male lev-
els in saliva. The testosterone-like immunoreactivity
was detectable even after organic extraction, support-
ing the hypothesis that the nature of this immunoreac-
tivity is similar to that of other steroid hormones. Only
one type of salivette, which did not contain glue and
was not prepared with citric acid for the stimulation of
salivary flow, did not demonstrate significant testoste-
rone-like immunoreactivity.
In futher experiments we compared this sampling
method to direct sampling in a glass tube. Forty-eight
medical students tested both sampling methods, one
method immediately following the other. The sampling
method using the salivettes led to lower matrix effects
(i.e. contamination with food particles) than the direct
colecting of saliva in a glass tube. In addition, most of
the volunteers felt the salivettes to be a more comfort-
able and more hygienic sampling method.
Up to now the achievement of constant serum lev-
els in a physiological range has been the main phar-
maco-kinetic goal when searching for new testoste-
rone preparations. Salivary testosterone reflects the
bioactive testosterone fraction (1, 2, 38, 43, 44). The
measurement of this variable is of interest as a mean-
ingful criterion for the effectiveness of an androgen
preparation.
Due to the close link between sperm production and
male hormones, endocrinological suppression of
sperm production is parallel with suppression of an-
drogen production. Thus androgen replacement ther-
apy plays an important role in the development of
methods for male contraception.
This study confirms both the adequacy of measure-
ment of salivary testosterone as a monitoring system
and testosterone buciclate as an androgen ester with
desirable pharmacokinetics for testosterone replace-
ment therapy: after administration of testosterone bu-
ciclate the course of the salivary testosterone curve
and the serum testosterone curve behaved similarly.
Both salivary testosterone and serum testosterone in-
creased to normal levels and were maintained in a
physiological range for seven weeks after a single in-
jection of 600 mg of testosterone buciclate. After ad-
ministration of 200 mg of testosterone buciclate, how-
ever, salivary testosterone levels as well as serum
testosterone levels did not increase (Fig. 2).
A negative correlation of salivary testosterone with
serum SHBG reflects the important role of circulating
SHBG on the amount of biologically active testoste-
rone and salivary testosterone. According to the thesis
that only the non-SHBG-bound testosterone is bioac-
tive and reflected by salivary testosterone, high SHBG-
levels are associated with low salivary testosterone
levels and vice versa. Furthermore, a positive correla-
tion between salivary testosterone and serum oestrad-
iol, which is one of the co-regulators of SHBG synthesis
in the liver, could be explained by a displacement of
bound androgens by increasing levels of oestradiol
and vice versa.
In summary, we have established a new method for
the measurement of testosterone in saliva using the
streptavidin-biotin tracer as a tool. The new ultrasensi-
tive method is fast, non-isotopic and requires a sample
volume of not more than 180 µl for extraction and du-
plicate determination. In addition, the new TR-FIA was
applied to a clinical phase I study, in which the new
long-acting androgen ester, testosterone buciclate,
was tested as a substitution therapy for male hypogon-
adism. Its favourable pharmacodynamics and pharma-
cokinetics, as shown previously by monitoring testos-
terone in serum (21), were confirmed by monitoring its
bioactive fraction by multiple consecutive measure-
ments of salivary testosterone.
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